标题
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents
作者
关键词
Tenofovir, Efavirenz, Atazanavir, Virological Failure, Rifabutin
出版物
DRUGS
Volume 75, Issue 13, Pages 1483-1497
出版商
Springer Nature
发表日期
2015-08-04
DOI
10.1007/s40265-015-0446-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Raltegravir: first in class HIV integrase inhibitor
- (2016) Zelalem Temesgen Therapeutics and Clinical Risk Management
- GSK1265744 Demonstrates Robust In Vitro Activity Against Various Clades of HIV-1
- (2015) Sharon L. Karmon et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents
- (2015) Rolando M. Viani et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
- (2015) S. Nachman et al. Journal of the Pediatric Infectious Diseases Society
- Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
- (2014) J. M. Custodio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
- (2014) Ivy Song et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
- (2014) François Raffi et al. LANCET
- Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
- (2014) Anton Pozniak et al. LANCET INFECTIOUS DISEASES
- Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
- (2014) Nicholas I. Paton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
- (2014) Lee D. Fader et al. ACS Medicinal Chemistry Letters
- Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
- (2013) Stephen Castellino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years
- (2013) S. Nachman et al. CLINICAL INFECTIOUS DISEASES
- Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
- (2013) Mackenzie L. Cottrell et al. CLINICAL PHARMACOKINETICS
- Next-Generation Integrase Inhibitors
- (2013) Sharon L. Karmon et al. DRUGS
- Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents
- (2013) Srinivasan Ramanathan et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) David A. Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Nathan Clumeck et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
- (2013) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection
- (2013) Bhavik M. Shah et al. PHARMACOTHERAPY
- Raltegravir in the prevention of mother-to-child transmission of HIV-1
- (2012) Aseel Hegazi et al. AIDS
- Genetic Diversity and Naturally Polymorphisms in HIV Type 1 Integrase Isolates from Maputo, Mozambique: Implications for Integrase Inhibitors
- (2012) Michelli F. Oliveira et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Elvitegravir: a once-daily inhibitor of HIV-1 integrase
- (2012) Todd Wills et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection
- (2012) Eduardo Gotuzzo et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults
- (2012) Mark R. Underwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin
- (2012) Kelly E. Dooley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Predictors of Antiretroviral Medication Adherence Among a Diverse Cohort of Adolescents With HIV
- (2012) Sulachni Chandwani et al. JOURNAL OF ADOLESCENT HEALTH
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Tolerability of HIV integrase inhibitors
- (2012) Frederick J. Lee et al. Current Opinion in HIV and AIDS
- Pharmacology of HIV integrase inhibitors
- (2012) Jessica L. Adams et al. Current Opinion in HIV and AIDS
- Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
- (2011) Ivy Song et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results
- (2011) Jacques Reynes et al. HIV CLINICAL TRIALS
- Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals
- (2011) Akil Jackson et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers
- (2011) P. Patel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor
- (2011) Diana M. Brainard et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents
- (2011) Verónica Briz et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
- (2011) Geoffrey S. Gottlieb et al. PLoS One
- High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women
- (2010) Denise A Mckeown et al. AIDS
- Natural Polymorphisms of integrase Among HIV Type 1-Infected South African Patients
- (2010) Muhammad Q. Fish et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and Maraviroc
- (2010) Srinivasan Ramanathan et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir
- (2010) Filippo Canducci et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
- (2010) Joseph J Eron et al. LANCET
- Raltegravir in the management of HIV-infected patients
- (2010) Hans-Juergen Stellbrink Drug Design Development and Therapy
- Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus
- (2009) Isabelle Thuret et al. AIDS
- Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies
- (2009) Filippo Canducci et al. AIDS
- Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir
- (2009) W. D. Hanley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir
- (2009) L. A. Wenning et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
- (2009) S. Min et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
- (2008) Avy Violari et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started